

Ontario Public Drug Programs

Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program

February 21, 2017

Effective **February 28, 2017**, the following hepatitis C drug products will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients for the treatment of hepatitis C.

- Harvoni (ledipasvir/sofosbuvir)
- Sovaldi (sofosbuvir)
- Epclusa (sofosbuvir/velpatasvir)
- Zepatier (elbasvir/grazoprevir)
- Daklinza (daclatasvir)
- Sunvepra (asunaprevir)
- Ibavyr (ribavirin)

The above drugs will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as Limited Use (LU) benefits.

Health care providers are advised to refer to the Formulary for information about the specific reimbursement criteria applicable to each of the funded hepatitis C drugs.

The range of funded hepatitis C drug products will enable funding consideration for patients with most of the common or mixed genotypes in Ontario when the specified criteria are met.

The full details of the LU criteria will be also be posted in the February 2017 monthly Formulary update at:

www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx

For more information, refer to the Frequently Asked Questions (FAQs) for healthcare providers and patients.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282